Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: ARCoV mRNA-LNP; COVID-19 mRNA vaccine - People's Liberation Army (PLA) Academy of Military Sciences/Suzhou Abogen Biosciences/Walvax Biotechnology; SARS-CoV-2 mRNA vaccine - People's Liberation Army (PLA) Academy of Military Sciences/Suzhou Abogen Biosciences/Walvax Biotechnology

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Academy of Military Science of the Chinese Peoples Liberation Army; Suzhou Abogen Biosciences; Walvax Biotechnology
  • Developer Suzhou Abogen Biosciences; Walvax Biotechnology
  • Class COVID-19 vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in China (Parenteral)
  • 22 Jul 2021 Phase-III clinical trials in COVID-2019 infections (Prevention) in Mexico, Indonesia (IM) (NCT04847102)
  • 15 Apr 2021 Walvax Biotechnology plans a phase III trial forCOVID-2019 infections (Prevention) (IM) in the May 2021 (NCT04847102)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top